Meeting
2020 ASCO Virtual Scientific Program
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer (NSCLC) overexpressing PD-L1: Early results of the FoRECATT Study.
Authors
Vincenzo Di Noia
Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Oncological Sciences, Catholic University of the Sacred Heart, Rome, Italy
Vincenzo Di Noia , Ettore D'Argento , Sara Pilotto , Carmine Carbone , Emanuele Vita , Giovanni Luca Ceresoli , Giordano D. Beretta , Giampaolo Tortora , Emilio Bria
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9598)
DOI
10.1200/JCO.2020.38.15_suppl.9598
Abstract #
9598
Poster Bd #
364
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.
First Author: Maysa Vilbert
Poster
2023 ASCO Annual Meeting
Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
First Author: Rachel Frascati
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal